Blueprint Medicines: Q4 Earnings Snapshot
By AP News
Published - Feb 16, 2023, 07:24 AM ET
Last Updated - Jun 22, 2023, 09:18 PM EDT
CAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Blueprint Medicines Corp. (BPMC) on Thursday reported a loss of $158.6 million in its fourth quarter.
On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of $2.65.
The results beat Wall Street expectations. The average estimate of 11 analysts surveyed by Zacks Investment Research was for a loss of $2.73 per share.
The cancer drug developer posted revenue of $38.8 million in the period, also surpassing Street forecasts. Ten analysts surveyed by Zacks expected $32.7 million.
